Understanding The Potential Role of WDR45B as A Drug Target and Biomarker
Understanding The Potential Role of WDR45B as A Drug Target and Biomarker
WDR45B (Wiskott-Aldrich Research Base 45B) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and function have made it an attractive target for researchers to study, and its potential as a drug or biomarker has generated a lot of interest in the scientific community.
WDR45B is a RNA molecule that is located in the nucleus of the human chromosomes. It is characterized by its ability to interact with proteins, which is essential for its function. WDR45B has a unique structure, with a length of 29.2 kilobases (kb) and a highly conserved open reading frame (ORF) that is similar to that of other RNA molecules.
The WDR45B ORF is composed of 11 exons that are involved in the synthesis of a protein with a molecular weight of approximately 45 kDa. This protein is known as WDR45B protein and is a key regulator of the immune response and inflammation.
WDR45B has been shown to play a crucial role in the regulation of immune cell function, including the T cell response. It has been shown to regulate the expression of genes involved in the development and activation of T cells, as well as the regulation of their function.
WDR45B has also been shown to be involved in the regulation of inflammation. It has been shown to play a role in the regulation of the production of pro-inflammatory cytokines, such as TNF-alpha and IL-12, and in the regulation of their function.
WDR45B has also been shown to be involved in the regulation of cell survival. It has been shown to play a role in the regulation of cell apoptosis, which is a natural process that helps to remove damaged or dysfunctional cells from the body.
WDR45B has also been shown to be involved in the regulation of gene expression. It has been shown to interact with proteins involved in the regulation of gene expression, including STAT3, a transcription factor that is involved in the regulation of gene expression.
WDR45B has been shown to play a role in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, studies have shown that high levels of WDR45B are associated with an increased risk of developing cancer, and that inhibiting its function may be a potential therapeutic approach for cancer treatment.
In addition to its potential as a drug target, WDR45B has also been shown to be a potential biomarker for various diseases. For example, studies have shown that WDR45B is downregulated in the brains of individuals with Alzheimer's disease, and that increasing its levels may be a potential therapeutic approach for the disease.
WDR45B has also been shown to be downregulated in the blood vessels of individuals with cardiovascular disease, and that increasing its levels may be a potential therapeutic approach for the disease.
In conclusion, WDR45B is a non-coding RNA molecule that has a unique structure and function. Its potential as a drug target and biomarker has generated a lot of interest in the scientific community, and further research is needed to fully understand its role in the regulation of immune cell function, inflammation, cell survival, and gene expression.
Protein Name: WD Repeat Domain 45B
Functions: Component of the autophagy machinery that controls the major intracellular degradation process by which cytoplasmic materials are packaged into autophagosomes and delivered to lysosomes for degradation (PubMed:28561066). Binds phosphatidylinositol 3-phosphate (PtdIns3P), and other phosphoinositides including PtdIns(3,5)P2, forming on membranes of the endoplasmic reticulum upon activation of the upstream ULK1 and PI3 kinases and is recruited at phagophore assembly sites where it regulates the elongation of nascent phagophores downstream of WIPI2 (PubMed:28561066, PubMed:30797857). In the cellular response to starvation, may also function together with the TSC1-TSC2 complex and RB1CC1 in the inhibition of the mTORC1 signaling pathway (PubMed:28503735)
The "WDR45B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about WDR45B comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
WDR46 | WDR47 | WDR48 | WDR49 | WDR5 | WDR53 | WDR54 | WDR55 | WDR59 | WDR5B | WDR6 | WDR62 | WDR64 | WDR7 | WDR70 | WDR72 | WDR73 | WDR74 | WDR75 | WDR76 | WDR77 | WDR81 | WDR82 | WDR82P1 | WDR83 | WDR83OS | WDR86 | WDR86-AS1 | WDR87 | WDR88 | WDR89 | WDR90 | WDR91 | WDR93 | WDR97 | WDSUB1 | WDTC1 | WEE1 | WEE2 | WEE2-AS1 | WFDC1 | WFDC10A | WFDC10B | WFDC11 | WFDC12 | WFDC13 | WFDC2 | WFDC21P | WFDC3 | WFDC5 | WFDC6 | WFDC8 | WFDC9 | WFIKKN1 | WFIKKN2 | WFS1 | WHAMM | WHAMMP1 | WHAMMP2 | WHAMMP3 | WHRN | WIF1 | WIPF1 | WIPF2 | WIPF3 | WIPI1 | WIPI2 | WIZ | WLS | WNK1 | WNK2 | WNK3 | WNK4 | Wnt | WNT1 | WNT10A | WNT10B | WNT11 | WNT16 | WNT2 | WNT2B | WNT3 | WNT3A | WNT4 | WNT5A | WNT5B | WNT6 | WNT7A | WNT7B | WNT8A | WNT8B | WNT9A | WNT9B | WRAP53 | WRAP73 | WRN | WRNIP1 | WSB1 | WSB2 | WSCD1
